Mander AP

Latest

Accounting for variation in the required sample size in the design of group-sequential trials
A stochastically curtailed two-arm randomised phase II trial design for binary outcomes
The Adaptive designs CONSORT Extension (ACE) statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Sample size re-estimation in crossover trials: Application to the AIM HY-INFORM study
Two-stage adaptive designs for three-treatment bioequivalence studies
A review of perspectives on the use of randomization in phase II oncology trials
Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables
Admissible multiarm stepped‐wedge cluster randomized trial designs
Re-formulating Gehan's design as a flexible two-stage single-arm trial
Calculations involving the multivariate normal and multivariate t distributions with and without truncation
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design
Group sequential crossover trial designs with strong control of the familywise error rate
Blinded and unblinded sample size reestimation in crossover trials balanced for period
Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials
Group sequential clinical trial designs for normally distributed outcome variables
An optimised multi-arm multi-stage clinical trial design for unknown variance
Adaptive designs in clinical trials: Why use them, and how to run and report them
Group sequential designs for stepped-wedge cluster randomised trials
Stepped wedge cluster randomized controlled trial designs: A review of reporting quality and design features
Do single-arm trials have a role in drug development plans incorporating randomised trials?
Correcting for multiple-testing in multi-arm trials: Is it necessary and is it done?
Minimizing the maximum expected sample size in two-stage phase II clinical trials with continuous outcomes
Optimal multistage designs for randomised clinical trials with continuous outcomes
Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected
Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points